Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of March 2012. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding a new issue of securities.
Key Financial Metrics and Capital Structure
The filing details a specific capital raise rather than periodic financial performance metrics such as revenue or profit.
- Securities Issued: 183,000 Ordinary Shares.
- Total Consideration: AUD$29,217.
- Issue Date: March 1, 2012.
- Post-Issue Capital: 295,701,018 Ordinary Shares quoted on the ASX.
- Unlisted Options: 29,194,925 options outstanding across various plans (PBTAB, PBTAI, PBTAK, PBTAM, PBTAO, PBTAQ, PBTAS, PBTAU).
The filing text does not provide clear values for revenue, net profit, operating cash flow, margins, debt levels, or liquidity ratios.
Material Changes
The primary material change is the issuance of 183,000 new ordinary shares, increasing the total quoted share count. The new shares rank pari passu with existing ordinary shares from the date of allotment. The filing notes this is part of an ongoing placement, with more tranches expected to be allotted in the future.
Guidance, Outlook, and Management Commentary
Purpose of Issue: The proceeds are designated to fund the Company's current clinical development, research programs, and working capital.
Dividend Policy: Unchanged.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard nature of clinical development funding. The company warrants compliance with the Corporations Act and that the issue is not for an illegal purpose.
Investor Verification Checklist
- Verify the effective price per share implied by the total consideration (AUD$29,217) for 183,000 shares.
- Confirm the status of the "ongoing placement" and whether subsequent tranches have been issued.
- Review the terms and expiry dates of the 29,194,925 unlisted options to assess potential future dilution.
- Check subsequent filings for updates on the clinical development programs funded by this capital raise.